Warning: Undefined variable $zfal in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 525
Deprecated: str_replace(): Passing null to parameter #3 ($subject) of type array|string is deprecated in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 525
Warning: Undefined variable $sterm in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 530
Warning: Undefined variable $sterm in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 531
English Wikipedia
Nephropedia Template TP (
Twit Text
DeepDyve Pubget Overpricing |
lüll CD20-targeted therapy: a breakthrough in the treatment of non-Hodgkin s lymphoma van Meerten T; Hagenbeek ANeth J Med 2009[Jul]; 67 (7): 251-9Targeting the CD20 antigen on B lymphocytes with the monoclonal antibody rituximab has greatly improved the outcome of patients with B-cell malignancies. Despite the success of rituximab, resistance occurs in about half of the patients, resulting in non-response to treatment or early relapse of the original disease. A better understanding of the mechanism of rituximab resistance has lead to the development of novel, improved anti-CD20 antibodies. This review describes the development of CD20-targeted therapy from its historical background towards the next generation of anti-CD20 monoclonal antibodies and explains new strategies to overcome resistance.|Animals[MESH]|Antibodies, Monoclonal, Murine-Derived[MESH]|Antibodies, Monoclonal/*administration & dosage/immunology[MESH]|Antigens, CD20/*immunology[MESH]|Antineoplastic Agents/*administration & dosage/immunology[MESH]|B-Lymphocytes/immunology[MESH]|Drug Delivery Systems/*methods[MESH]|Humans[MESH]|Lymphoma, Non-Hodgkin/*drug therapy/immunology[MESH]|Rituximab[MESH] |